Takeda
Takeda Pharmaceutical Company Limited is Japan's largest pharmaceutical company and one of the top ten global biopharmaceutical companies by revenue, with a significant and growing clinical trials presence following major acquisitions including Shire (2019) and ARIAD Pharmaceuticals (2017). Headquartered in Tokyo with its global R&D center in Cambridge, Massachusetts, Takeda's trial portfolio focuses on oncology/hematology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
In oncology, Takeda's most recognized asset is brigatinib (Alunbrig), an ALK inhibitor for ALK-positive non-small cell lung cancer, and ixazomib (Ninlaro), the first oral proteasome inhibitor approved for multiple myeloma. Through the ARIAD acquisition, Takeda gained ponatinib (Iclusig) for CML and ALL with the T315I mutation. The hematology/rare disease portfolio — substantially expanded by the Shire acquisition — includes treatments for hemophilia A and B, von Willebrand disease, hereditary angioedema, Fabry disease, and Gaucher disease, each supported by ongoing natural history studies, registry-based surveillance, and interventional trials.
Takeda's gastroenterology program includes vedolizumab (Entyvio), a gut-selective integrin inhibitor approved for Crohn's disease and ulcerative colitis, with active trials in primary sclerosing cholangitis and other GI inflammatory conditions. The neuroscience pipeline targets attention deficit hyperactivity disorder, major depressive disorder, and bipolar disorder. Takeda participates in the Innovative Medicines Initiative and other public-private partnerships for antimicrobial resistance, dengue, and norovirus vaccine development.